NCT06784765 Preventive Use of PIPAC in Locally Advanced Gastric Cancer.
| NCT ID | NCT06784765 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Research Oncology and Transplantology Center, Kazakhstan |
| Condition | Gastric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-01-15 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2025-01-15 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related mortality. In patients with locally advanced gastric cancer, multimodal treatment strategies, including perioperative chemotherapy, have significantly improved survival rates. Despite these advances, peritoneal carcinomatosis (PC) remains a serious problem, occurring in 60% of cases after radical surgery. PC is associated with poor prognosis and limited treatment options. Intra-abdominal chemotherapy, particularly hyperthermic intraperitoneal chemoperfusion (HIPEC), has demonstrated advantages in the treatment of PC. However, a new technique, pressurized intraperitoneal aerosolized chemotherapy (PIPAC), is emerging as a promising alternative. PIPAC delivers chemotherapeutic agents directly to the peritoneal surface as an aerosol, allowing deeper penetration of drugs into tumor implants while minimizing toxicity and invasiveness. This study hypothesizes that the addition of PIPAC as a preoperative treatment for patients with locally advanced gastric cancer may reduce the incidence of peritoneal carcinomatosis compared to standard therapy. The primary objective of this study is to determine whether preoperative PIPAC reduces the incidence of peritoneal carcinomatosis in these patients.
Eligibility Criteria
Adults aged 18-70 years with histologically confirmed locally advanced gastric adenocarcinoma (T3-4N0-3M0), ECOG performance status 0-2, and negative peritoneal cytology. Inclusion Criteria: 1. Signed informed consent 2. Aged 18-70 years 3. ECOG performance status 0-2 4. Histologically confirmed adenocarcinoma of the stomach (T3-4N0-3M0) 5. Negative peritoneal cytology from diagnostic laparoscopy 6. No prior chemotherapy or radiotherapy Exclusion Criteria: 1. Presence of distant metastases 2. Positive peritoneal cytology 3. Previous cancer treatment (chemotherapy, radiotherapy, or surgery) 4. Severe comorbid conditions contraindicating surgery or chemotherapy 5. Pregnancy or lactation 6. Known hypersensitivity to study drugs
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06784765 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06784765 currently recruiting?
Yes, NCT06784765 is actively recruiting participants. Contact the research team at altay.kerimkulov@gmail.com for enrollment information.
Where is the NCT06784765 trial being conducted?
This trial is being conducted at Astana, Kazakhstan.
Who is sponsoring the NCT06784765 clinical trial?
NCT06784765 is sponsored by National Research Oncology and Transplantology Center, Kazakhstan. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.